Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2020 16:51 ET | Source: uniQure Inc.

uniQure Announces Significant Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting

LEXINGTON, Mass. and AMSTERDAM, April 28, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
April 17, 2020 07:00 ET | Source: uniQure Inc.

uniQure Announces the Nomination of Leonard E. Post, Ph.D. to its Board of Directors

LEXINGTON, Mass. and AMSTERDAM, April 17, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
March 30, 2020 07:00 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Investor Conferences in April

LEXINGTON, Mass. and AMSTERDAM, March 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
March 26, 2020 07:00 ET | Source: uniQure Inc.

uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B

LEXINGTON, Mass. and AMSTERDAM, March 26, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet...
March 03, 2020 07:00 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences in March

LEXINGTON, Mass. and AMSTERDAM, March 03, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
March 02, 2020 16:05 ET | Source: uniQure Inc.

uniQure Announces 2019 Financial Results and Highlights Recent Company Progress

~ Patient Dosing Nearly Completed in Phase III HOPE-B Trial of Etranacogene Dezaparvovecin Hemophilia B ~ ~ First Patient Procedure in Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease...
March 02, 2020 16:05 ET | Source: uniQure Inc.

uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters

~ Gen-X Will Work with uniQure During an Exclusivity Period to Identify Novel Promoters for uniQure’s Product Portfolio ~ ~ uniQure Receives Option to Acquire Gen-X Business for Use in Gene Therapy ~...
February 27, 2020 07:00 ET | Source: uniQure Inc.

uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference

~ Up to Two Years of Follow-up in Large Transgenic Huntington’s Disease Model Demonstrates Stable mHTT Protein Lowering ~ ~ Novel Preclinical Data Demonstrates Successful Lowering of Pathogenic Exon...
February 04, 2020 07:00 ET | Source: uniQure Inc.

uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
January 31, 2020 07:00 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences in February

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 31, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...